Targeting cancer with power and precision

Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) is a late-stage, clinical oncology company advancing novel product candidates based upon the Company’s targeted protein therapeutics (TPTs) platform. TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. Eleven’s lead TPT, Vicinium™, is currently in a Phase 3 trial in non-muscle invasive bladder cancer, with topline three-month data expected in mid-2018. The Company believes its TPT approach offers significant advantages in treating cancer over existing antibody drug conjugate technologies. The Company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads that require tumor cell proliferation and face multi-drug resistant mechanisms. Additionally, the Company believes that its TPT’s cancer cell-killing properties promote an anti-tumor immune response that will potentially combine well with immune oncology drugs such as checkpoint inhibitors.

Year Invested: 2010
Location: Cambridge, Mass.

Recent News

March 12, 2018
Enrollment Completed in Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer

March 5, 2018
Eleven Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference

February 8, 2018
Eleven Biotherapeutics to Present at 2018 BIO CEO & Investor Conference

Read More News

Associated Team Members

Abbie Celniker, Ph.D.

Mark Levin

Cary Pfeffer, M.D.